Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomized, placebo-controlled multi-center, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 [farglitazar] in chronic hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy

Next Previous
X
Search
Trial Profile

A double-blind, randomized, placebo-controlled multi-center, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 [farglitazar] in chronic hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Farglitazar (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

    • Most Recent Events

    • 15 Nov 2021 Results of an association between CTX-III and fibrotic resolution and shift in type III collagen remodeling as a function of fibrosis stage analysis presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
    • 26 Jun 2021 Results(n=127) predicting response to antifibrotic treatment, with a peroxisome proliferator activated receptor -y agonist, in patients with chronic hepatitis C presented at The International Liver Congress 2021
    • 23 May 2021 Results (n=46) assessing association between CTX-III and fibrotic resolution and shift in type III collagen remodeling as a function of fibrosis stagepresented at the Digestive Disease Week 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top